ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Baseline and follow-up tests for response assessment in multiple myeloma using IMWG consensus criteria

Baseline and follow-up tests for response assessment in multiple myeloma using IMWG consensus criteria
  Every response assessment timepoint (every cycle) If electrophoresis shows no measurable protein At suspected CR At suspected progression (clinical or biochemical)
SPEP (serum M-spike ≥1 g/dL[1])* X ◊◊ X X
Serum immunofixation (any) ◊◊ X X X
UPEP (urine M-spike ≥200 mg/24 hours) X ◊◊ X X
Urine immunofixation (any) ◊◊ X X ◊◊
Serum FLC
Serum M-spike <1 g/dL, urine M-spike <200 mg/24 hours, but involved immunoglobulin FLC is ≥10 mg/dL X ◊◊ X X
Any ◊◊ ◊◊ X X
Bone marrow aspirate/biopsy
Serum M-spike, urine M-spike, or involved immunoglobulin FLC not meeting above criteria but bone marrow plasma cell percentage ≥30% X
(to be done every three or four cycles till a plateau or complete response, or as clinically indicated and then at suspected progression)		 ◊◊ X ◊◊
Any ◊◊ ◊◊ X ◊◊
Plasmacytoma (PET imaging)
Serum M-spike, urine M-spike, involved Ig FLC or bone marrow not meeting above criteria, but at least one lesion that has a single diameter of ≥2 cm X
(to be done every three or four cycles till a plateau or complete response, or as clinically indicated, and then at suspected progression)		 ◊◊ X ◊◊
Any ◊◊ ◊◊ X ◊◊
Hemoglobin, serum calcium, creatinine (any) X ◊◊ ◊◊ X
IMWG: International Myeloma Working Group; CR: complete response; SPEP: serum protein electrophoresis; UPEP: urine protein electrophoresis; FLC: free light chain; X: test performed; ◊◊: test not performed.
* A baseline M-spike of ≥0.5 g/dL is acceptable if very good partial response or higher is the response endpoint to be measured and in situations where progression-free survival or time to progression are the endpoints of interest.
Reference:
  1. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2013; 28: 1122-08.
Reproduced from: Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17:e328. Table used with the permission of Elsevier Inc. All rights reserved.
Graphic 111430 Version 1.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟